Biocept

Biocept, Inc. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample. The company utilizes cell enrichment and extraction technology for the detection and analysis of circulating tumor DNA tests. It also offers services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies and clinical trial support and specific oncogenic alterations. Biocept was founded on May 12, 1997 and is headquartered in San Diego, CA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q1 2024

Biocept, Inc. is an oncology laboratory service company, which engages in the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. The company was founded on May 12, 1997 and is headquartered in San Diego, CA.

Speculative Spotlight: Biocept Is Undervalued Despite Commercial Progress

Biocept, Inc. (BIOC) CEO Michael Nall on Q3 2019 Results - Earnings Call Transcript

Biocept, Inc. (BIOC) CEO Michael Nall on Q2 2019 Results - Earnings Call Transcript

Shares of Biocept Inc. BIOC, +84.16% soared 86% on very heavy volume Monday, after the provider of liquid biopsy tests announced the commercial launch of Target Selector NGS Lung Panel, the liquid biopsy panel developed for lung cancer.

Biocept's stock soars on heavy volume after commercial launch of liquid biopsy test for lung cancer

Shares of Biocept Inc (NASDAQ: BIOC), a molecular diagnostics company specializing in biomarker analysis of circulating tumor-associated DNA, are making a strong upward move Monday.

Cancer Diagnostic Company Biocept's Stock Doubles In Value: What You Need To Know

Biocept, Inc. (BIOC) CEO Michael Nall on Q1 2019 Results - Earnings Call Transcript

Biocept, Inc. (BIOC) CEO Michael Nall on Q4 2018 Results - Earnings Call Transcript

News for Biocept Stock (BIOC)